Paraganglioma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
*<sup>111</sup>In-octreotide scintigraphy | *<sup>111</sup>In-octreotide scintigraphy | ||
*<sup>18</sup>F-fluorodeoxyglucose positron emission tomography | *<sup>18</sup>F-fluorodeoxyglucose positron emission tomography | ||
==References== | |||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] |
Revision as of 16:10, 14 September 2015
Paraganglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Paraganglioma other imaging findings On the Web |
American Roentgen Ray Society Images of Paraganglioma other imaging findings |
Risk calculators and risk factors for Paraganglioma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
123I-metaiodobenzylguanidine (MIBG) scintigraphy coupled with CT imaging can be used for diagnosis of paragnglioma.
Other Imaging Studies
Other imaging studies may include:
- 123I-metaiodobenzylguanidine (MIBG) scintigraphy
- 111In-octreotide scintigraphy
- 18F-fluorodeoxyglucose positron emission tomography